Skip to content
10-Q

Quarterly Report

Coya Therapeutics, Inc. COYA

0001193125-26-218201

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 23.46M sh
Shares Diluted Q1 2026 · Mar 31, 2026 22.64M sh
Shares Diluted Q1 2026 · Mar 31, 2025 16.72M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$6.21M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.83M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $50.72M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $46.82M
Stockholders Equity Q1 2026 · Mar 31, 2026 $48.97M
Stockholders Equity Q1 2026 · Dec 31, 2025 $43.03M
Stockholders Equity Q1 2026 · Mar 31, 2025 $33.37M
Stockholders Equity Q1 2026 · Dec 31, 2024 $39.58M
Current Liabilities Q1 2026 · Mar 31, 2026 $3.55M
Current Liabilities Q1 2026 · Dec 31, 2025 $5.87M
Total Liabilities Q1 2026 · Mar 31, 2026 $4.3M
Total Liabilities Q1 2026 · Dec 31, 2025 $6.92M
Current Assets Q1 2026 · Mar 31, 2026 $53.26M
Current Assets Q1 2026 · Dec 31, 2025 $49.94M
Total Assets Q1 2026 · Mar 31, 2026 $53.27M
Total Assets Q1 2026 · Dec 31, 2025 $49.95M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.32
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.44
Eps Basic Q1 2026 · Mar 31, 2026 −$0.32
Eps Basic Q1 2026 · Mar 31, 2025 −$0.44
Sga Expense Q1 2026 · Mar 31, 2026 $3.78M
Sga Expense Q1 2026 · Mar 31, 2025 $2.71M
Net Income Q1 2026 · Mar 31, 2026 −$7.21M
Net Income Q1 2026 · Mar 31, 2025 −$7.31M
Operating Income Q1 2026 · Mar 31, 2026 −$7.64M
Operating Income Q1 2026 · Mar 31, 2025 −$7.68M
Revenue Q1 2026 · Mar 31, 2026 $251.15K
Revenue Q1 2026 · Mar 31, 2025 $257.88K